NCT07611812

Completed

Real-World Patterns of Utilization of Lenalidomide-based Tri...

Fondazione IRCCS Policlinico San Matteo di Pavia Source

Compare

Other study identifiers

Sponsor study identifier

FIRE-Prime Recidive

Study Type

observational

Actual enrollment (reported)

100

Locations

1 country

Sites

1

Timeline

Study Start

February 4, 2021

Actual (reported)

Primary Completion

December 31, 2024

Actual (reported)

Study Completion

December 31, 2025

Actual (reported)

Brief Summary

To compare progression-free survival (PFS) in patients with first-relapse multiple myeloma treated with Rd-based "triplets" (Daratumumab + Rd (DaraRd) vs Carfilzomib + Rd (KRd) vs. Elotuzumab + Rd (EloRd) vs. Ixazomib + Rd (IxaRd))

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 100 participants
Study completion date: December 31, 2025
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
February 4, 2021
Actual (reported)
Primary Completion
December 31, 2024
Actual (reported)
Study Completion
December 31, 2025
Actual (reported)
First Submitted
May 14, 2026
Actual (reported)
First Posted
May 28, 2026
Actual (reported)

Last Updated: May 28, 2026
Status Verified: May 2026
Last Update Submitted: May 20, 2026

Conditions

First Relpase Multiple Mieloma Rd-base Triplet

Outcome Measures

Primary Outcomes (1)

Comparison of progression-free survival (PFS) in patients with multiple myeloma at first relapse treated with Rd-based "triplet" regimens (Daratumumab + Rd (DaraRd) vs Carfilzomib + Rd (KRd) vs Elotuzumab + Rd (EloRd) vs Ixazomib + Rd (IxaRd))
The study is expected to run for 24 months starting with the enrollment of the first patient in November 2020

Eligibility Criteria

Age18 Years+

Sexall

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients referred to the hematology department of the coordinating center and the participating centers

You may qualify if:

Patients with multiple myeloma (MM) at first relapse treated starting in January 2017 with RD-based triplets in accordance with current clinical practice

Sponsors & Collaborators

Fondazione IRCCS Policlinico San Matteo di Pavia
Otherlead

Study Sites (1)

Fondazione IRCCS Policlinico San Matteo

Pavia, 27100, Italy

Enrollment

100 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: MD

Study Record Dates

First Submitted

May 14, 2026

First Posted

May 28, 2026

Study Start

February 4, 2021

Actual (reported)

Age ≥18 years

Written informed consent signed by the patient

You may not qualify if:

the patient's refusal to participate

Contact the study team to confirm eligibility.

Primary Completion

December 31, 2024

Actual (reported)

Study Completion

December 31, 2025

Actual (reported)

Last Updated

May 28, 2026

Record last verified: 2026-05

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT07611812
Data provider: ClinicalTrials.gov
Source updated: 2026-05-28
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:24:50 UTC

Locations

IT(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations